Nemaura Medical is a medical devices business based in the US. Nemaura Medical shares (NMRD) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.00 – a decrease of 77.78% over the previous week. Nemaura Medical employs 36 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.00 |
|---|---|
| 52-week range | $0.00 - $0.39 |
| 50-day moving average | $0.03 |
| 200-day moving average | $0.06 |
| Wall St. target price | $1.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.39 |
Historical closes compared with the close of $0.004 from 2024-10-15
| 1 week (2024-10-09) | -77.78% |
|---|---|
| 1 month (2024-09-16) | -85.87% |
| 3 months (2024-07-16) | -90.00% |
| 6 months (2024-04-16) | -94.60% |
| 1 year (2023-10-16) | -98.46% |
|---|---|
| 2 years (2022-10-14) | -99.83% |
| 3 years (2021-10-15) | 5.83 |
| 5 years (2019-10-16) | 7.14 |
| Gross profit TTM | $-1,476,392 |
|---|---|
| Return on assets TTM | -81.19% |
| Return on equity TTM | -724.44% |
| Profit margin | 0% |
| Book value | $-0.62 |
| Market Capitalization | $121,055 |
TTM: trailing 12 months
We're not expecting Nemaura Medical to pay a dividend over the next 12 months.
Nemaura Medical's shares were split on a 1:10 basis on 4 December 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nemaura Medical shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nemaura Medical shares which in turn could have impacted Nemaura Medical's share price.
Over the last 12 months, Nemaura Medical's shares have ranged in value from as little as $0.003 up to $0.39. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Nemaura Medical's is -0.043. This would suggest that Nemaura Medical's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Nemaura Medical has bucked the trend.
Nemaura Medical Inc. , a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.